Saturday 17 October 2026
Export HSCS’s income statement to Excel — free account
HeartSciences Inc.
HSCS Healthcare Medical Devices
HeartSciences Inc.’s revenue for fiscal 2026 (year ended April 2026) was $4,300.00, down 2.27% from fiscal 2025. In the quarter to July 2026, revenue fell 46.2%, EPS grew 45.6% and free cash flow grew 18.2%, each against the same quarter a year earlier.
3.02
0.16
−5.03%
Follow HSCS
| Apr '26 | Apr '25 | Apr '24 | Apr '23 | Apr '22 | Apr '21 | Apr '20 | |
|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 2 | 6 | 5 | 1 | — | — |
Altman Z-Score |
(27.87) | (31.71) | (10.51) | (30.31) | — | — | — |
P/S ratio |
223.56 | 159.88 | 157.43 | 722.34 | 0.00 | 0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(66.36) | (74.39) | (20.19) | (70.95) | (105.64) | (91.54) | (103.25) |
P/Operating CF |
(3.05) | (2.07) | (2.06) | (3.61) | (4.73) | (4.73) | (4.73) |
P/B ratio |
22.73 | 16.08 | 0.44 | 29.18 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.57 | 29.18 | 0.00 | 0.00 | 0.00 |
EV/Sales |
180.54 | 121.11 | (88.72) | 624.44 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(0.56) | (0.34) | 0.30 | (1.01) | (2.58) | (2.58) | (2.58) |
EV/FCF |
(0.55) | (0.33) | 0.30 | (1.00) | (2.58) | (2.58) | (2.58) |
Quick Ratio |
0.34 | 0.30 | 3.32 | 0.91 | 0.27 | 0.65 | 0.44 |
Current Ratio |
0.53 | 0.59 | 4.20 | 1.47 | 0.56 | 1.47 | 1.35 |
Net Debt/EBITDA |
0.21 | 0.14 | 0.95 | 0.20 | (0.78) | (0.80) | (0.12) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 15.21% | 212.59% | 142.69% | 48.20% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 2.17 | (0.73) | (1.44) | 2.99 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
Operating CF/Net income |
0.81 | 0.85 | 0.92 | 0.91 | 0.75 | 1.00 | 1.01 |
Capex/Depreciation |
(0.07) | (0.07) | (0.63) | (0.09) | (0.01) | (0.02) | 0.00 |
Interest Coverage |
(11.17) | (16.69) | (17.81) | (25.14) | (12.67) | (19.37) | (2,727.29) |
| (4,252.05%) | (233.06%) | (175.04%) | 218.13% | 121.22% | 307.49% | 0.00% | |
| (192.75%) | (127.72%) | (103.28%) | (236.37%) | (240.41%) | (126.29%) | 0.00% | |
ROIC |
0.00% | 0.00% | (261.05%) | 0.00% | 0.00% | (1,369.82%) | 0.00% |
Return on Tangible Assets |
408.32% | 597.00% | (115.88%) | (686.88%) | 328.52% | (396.22%) | (468.14%) |
Average Days of Receivables |
0.00 | 365.00 | 0.00 | 0.00 | 58.30 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
66,023.26% | 99,684.09% | 15,476.34% | 47,325.00% | 20,843.75% | 6,673.44% | 3,177.88% |
Selling, General and Administrative Expense of Revenue |
129,683.72% | 90,202.27% | 18,493.01% | 70,278.85% | 11,905.56% | 3,416.41% | 2,697.66% |
Intangible Assets out of Total Assets |
0.31 | 0.38 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
30,520.93% | 5,679.55% | 2,177.42% | 4,775.00% | 718.06% | 96.48% | 0.00% |
Graham Net Nets |
(0.48) | (0.56) | 1.59 | (0.05) | (1.10) | (1.10) | (1.10) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 772.72 | 0.00 | 0.00 |
Earnings Yield |
(202.05%) | (266.67%) | (347.83%) | (97.04%) | (85.58%) | (85.58%) | (85.58%) |
Free Cash Flow Yield |
(145.94%) | (227.48%) | (189.32%) | (86.22%) | (64.61%) | (64.61%) | (64.61%) |
Revenue per Share |
0.00 | 0.00 | 0.05 | 0.07 | 0.43 | 0.77 | 0.01 |
Operating CF per Share |
(2.83) | (7.90) | (17.22) | (72.62) | (109.76) | (74.09) | (0.48) |
Capex per Share |
(0.02) | (0.03) | (0.36) | (0.23) | (0.06) | (0.02) | 0.00 |
Free Cash Flow per Share |
(2.85) | (7.93) | (17.58) | (72.85) | (109.82) | (74.11) | (0.48) |
Cash per Share |
0.63 | 1.17 | 16.48 | 20.89 | 27.66 | 21.86 | 0.06 |
Shareholders Equity per Share |
0.09 | 0.22 | 20.76 | 2.90 | (182.40) | (57.69) | 0.04 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.09 | 0.22 | 20.76 | 2.90 | (182.40) | (57.69) | 0.04 |
Free Cash Flow |
(7.47) | (7.44) | (6.20) | (5.79) | (3.65) | (2.45) | (3.84) |
Working Capital |
(2.28) | (1.53) | 5.60 | 0.86 | (1.54) | 0.52 | 0.40 |
Capital Expenditures |
(0.04) | (0.03) | (0.13) | (0.02) | 0.00 | 0.00 | (0.01) |
Net Current Asset Value |
(2.45) | (1.85) | 5.17 | (0.36) | (6.21) | (2.20) | (0.10) |
EV/EBIT |
0.00 | 0.00 | 0.29 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
10.35 | 6.86 | 6.74 | 3.52 | 0.13 | 0.03 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
15.96 | 6.52 | 2.03 | 3.21 | 2.62 | 0.35 | 0.15 |
Cash ROIC |
(396.79%) | (571.10%) | (47.20%) | (242.23%) | 524.08% | (156.83%) | (218.78%) |
Accounts Receivable Turnover |
0.00 | 1.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.01 | 0.01 | 0.01 | 0.00 | 0.02 | 0.03 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 |
Average Days of Payables |
64,544.17 | 61,223.95 | 26,818.52 | 82,307.50 | 32,096.90 | 11,454.86 | 1,187.33 |
Days of Inventory on Hand |
132,941.11 | 124,926.05 | 37,648.85 | 88,173.57 | 31,145.13 | 25,611.40 | 2,835.95 |
Average Receivables |
— | 0.00 | — | — | — | — | — |
Average Payables |
0.32 | 0.38 | 0.54 | 0.66 | 0.52 | 0.35 | — |
Average Inventory |
0.65 | 0.64 | 0.65 | 0.68 | 0.71 | 0.80 | — |
Average Assets |
4.74 | 6.86 | 6.40 | 2.69 | 2.01 | 1.94 | — |
Average Common Equity |
0.22 | 3.76 | 3.77 | (2.91) | (3.98) | (0.80) | — |
Columns are period end dates · fundamentals updated 1 Oct 2026